V1RD21 Inhibitors
V1RD21 Inhibitors are a specific class of chemical compounds that serve to impair the activity of the V1RD21 protein, a kinase that may be centrally involved in various signaling pathways. Staurosporine, a comprehensive kinase inhibitor, effectively blocks the ATP-binding site of V1RD21, thereby halting its ability to phosphorylate substrates and disrupting its signaling capabilities. Similarly, multi-targeted receptor tyrosine kinase inhibitors like Sunitinib and Dasatinib prevent V1RD21activation by competing with ATP for the kinase domain, which is essential for its autophosphorylation and subsequent activation. These inhibitors, by their action, ensure that V1RD21 is unable to partake in its typical cellular functions, which might include signal transduction and various regulatory roles. Other V1RD21 inhibitors such as LY294002, Wortmannin, and Rapamycin target elements upstream of V1RD21 within key signaling cascades such as PI3K/AKT/mTOR. By disrupting these pathways, these inhibitors preclude the necessary upstream signals that may be required for V1RD21 activation or regulation, thus preventing its contribution to cell proliferation, survival, and other vital processes.
The inhibitors' actions are not limited to the direct blockade of V1RD21's kinase activity; they also encompass the modulation of related signaling pathways which indirectly influence V1RD21 function. PD98059, U0126, and SB203580 specifically inhibit the MAPK/ERK and p38 MAP kinase pathways, respectively, which could be implicated in the regulation or activation of V1RD21. The inhibition of these pathways suggests a potential reduction in V1RD21 activity, considering its dependence on phosphorylation events within these cascades for its activity. In a similar vein, SP600125 targets JNK, a kinase involved in apoptosis and proliferation signaling, indicating that V1RD21 activity might be curtailed if it is associated with JNK-mediated cellular responses. In addition, Gefitinib and Lapatinib's inhibition of EGFR and HER2/neu may lead to a downstream decrease in V1RD21 activity if the protein is involved in EGFR or HER2/neu mediated signaling. Through these multifaceted mechanisms, V1RD21 inhibitors collectively ensure the downregulation of V1RD21's functional activity, targeting the protein directly as well as indirectly by altering the signaling landscape that governs its operation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. V1RD21, being a kinase, has its activity disrupted as staurosporine binds to its ATP-binding site, preventing the transfer of phosphate groups to substrate proteins, thus inhibiting its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 prevents the downstream activation of AKT, which may be necessary for the full activation of V1RD21 or its localization to specific cellular compartments. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of the MAPK/ERK pathway. It inhibits MEK, which prevents the activation of ERK. This disruption can lead to a decrease in V1RD21 activity if the MAPK/ERK pathway is involved in its regulation or activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR (mechanistic target of rapamycin), which is a central component of the PI3K/AKT/mTOR pathway. By inhibiting mTOR, Rapamycin can decrease the phosphorylation and activity of downstream targets, potentially including V1RD21 if it is regulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is involved in stress responses. Inhibition of p38 MAPK by SB203580 could decrease the activation of V1RD21 if it is implicated in pathways responsive to cellular stress. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of ERK1/2. This inhibition can reduce the activity of V1RD21 if it is part of the MAPK/ERK signaling cascade that regulates its function or expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which participates in the regulation of apoptosis and cell proliferation. By inhibiting JNK, SP600125 could reduce V1RD21 activity if it is involved in these JNK-mediated processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of PI3K. By inhibiting PI3K, wortmannin can suppress the AKT signaling pathway, which could reduce the activity of V1RD21 if the protein operates downstream or is modulated by the PI3K/AKT pathway. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor. It can inhibit V1RD21 activity by competing with ATP for binding to the kinase domain, thus preventing its autophosphorylation and subsequent activation of its signaling functions. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. It inhibits the activity of V1RD21 by binding to its active site, thereby blocking substrate access and preventing downstream signaling that would lead to the protein's activation. | ||||||